These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35522122)

  • 1. Eosinophilic cellulitis in response to BNT162b2 COVID-19 vaccination.
    Ikediobi O; Eichenfield DZ; Barrio VR
    Pediatr Dermatol; 2022 Sep; 39(5):823-824. PubMed ID: 35522122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum polyethylene glycol-specific IgE and IgG in patients with hypersensitivity to COVID-19 mRNA vaccines.
    Mouri M; Imamura M; Suzuki S; Kawasaki T; Ishizaki Y; Sakurai K; Nagafuchi H; Matsumura N; Uchida M; Ando T; Yoshioka K; Ooka S; Sugihara T; Miyoshi H; Mori M; Okada T; Yamaguchi M; Kunishima H; Kato M; Kawahata K
    Allergol Int; 2022 Oct; 71(4):512-519. PubMed ID: 35718709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eosinophilic cellulitis after BNT162b2 mRNA Covid-19 vaccine.
    de Montjoye L; Marot L; Baeck M
    J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):e26-e28. PubMed ID: 34547138
    [No Abstract]   [Full Text] [Related]  

  • 4. A Case of Myocarditis Presenting With a Hyperechoic Nodule After the First Dose of COVID-19 mRNA Vaccine.
    Park S; You J
    J Korean Med Sci; 2022 Apr; 37(16):e131. PubMed ID: 35470603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
    Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
    JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
    Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
    BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study.
    Xiong X; Wong CKH; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng FWT; Lau KTK; Lee CH; Woo YC; Lui DTW; Wong ICK
    Thyroid; 2022 May; 32(5):505-514. PubMed ID: 35216517
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute myocarditis following a third dose of COVID-19 mRNA vaccination in adults.
    Simone A; Herald J; Chen A; Nayak R; Shen YA; Lee MS
    Int J Cardiol; 2022 Oct; 365():41-43. PubMed ID: 35870635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed systemic urticarial reactions following mRNA COVID-19 vaccination.
    Pitlick MM; Joshi AY; Gonzalez-Estrada A; Chiarella SE
    Allergy Asthma Proc; 2022 Jan; 43(1):40-43. PubMed ID: 34983709
    [No Abstract]   [Full Text] [Related]  

  • 10. IgA Nephropathy with Gross Hematuria Following COVID-19 mRNA Vaccination.
    Nihei Y; Kishi M; Suzuki H; Koizumi A; Yoshida M; Hamaguchi S; Iwasaki M; Fukuda H; Takahara H; Kihara M; Tomita S; Suzuki Y
    Intern Med; 2022 Apr; 61(7):1033-1037. PubMed ID: 35110484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psoriasis flare-up after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: report of twelve cases from a single centre.
    Koumaki D; Krueger-Krasagakis SE; Papadakis M; Katoulis AC; Gkiaouraki I; Zografaki K; Mylonakis D; Krasagakis K
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e411-e415. PubMed ID: 35075691
    [No Abstract]   [Full Text] [Related]  

  • 12. Keratoplasty Rejection After the BNT162b2 messenger RNA Vaccine.
    Wasser LM; Roditi E; Zadok D; Berkowitz L; Weill Y
    Cornea; 2021 Aug; 40(8):1070-1072. PubMed ID: 34029238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
    Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
    Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study.
    Haslak F; Gunalp A; Cebi MN; Yildiz M; Adrovic A; Sahin S; Barut K; Kasapcopur O
    Int J Rheum Dis; 2022 Mar; 25(3):353-363. PubMed ID: 34978376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
    Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
    JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Rejection Following COVID-19 Vaccination in Penetrating Keratoplasty in a Young Male - A Case Report and Review of Literature.
    Marziali E; Pasqualetti R; Bacci G; de Libero C; Caputo R
    Ocul Immunol Inflamm; 2023 Aug; 31(6):1226-1229. PubMed ID: 35914312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric Wells syndrome (eosinophilic cellulitis) after vaccination: A case report and review of the literature.
    Yu AM; Ito S; Leibson T; Lavi S; Fu LW; Weinstein M; Skotnicki SM
    Pediatr Dermatol; 2018 Sep; 35(5):e262-e264. PubMed ID: 29998475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events following BNT162b2 mRNA COVID-19 vaccination among healthcare workers: A single-centre experience in Malaysia.
    Gan LL; Zahidah AR; Hazirah T; Nabilah HK; Aisyah Z; Amin INM; Ng DCE
    Med J Malaysia; 2022 May; 77(3):300-305. PubMed ID: 35638485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.